- Home
- OMCC vs ACRV Comparison
OMCC vs ACRV Comparison
Compare OMCC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- ACRV
- Stock Information
- Founded
- OMCC 1985
- ACRV 2018
- Country
- OMCC United States
- ACRV United States
- Employees
- OMCC N/A
- ACRV N/A
- Industry
- OMCC
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- OMCC
- ACRV Health Care
- Exchange
- OMCC NYSE
- ACRV Nasdaq
- Market Cap
- OMCC 36.8M
- ACRV 40.4M
- IPO Year
- OMCC N/A
- ACRV 2022
- Fundamental
- Price
- OMCC $6.17
- ACRV $1.34
- Analyst Decision
- OMCC
- ACRV Buy
- Analyst Count
- OMCC 0
- ACRV 7
- Target Price
- OMCC N/A
- ACRV $17.60
- AVG Volume (30 Days)
- OMCC 6.6K
- ACRV 379.9K
- Earning Date
- OMCC 08-25-2025
- ACRV 08-12-2025
- Dividend Yield
- OMCC N/A
- ACRV N/A
- EPS Growth
- OMCC N/A
- ACRV N/A
- EPS
- OMCC N/A
- ACRV N/A
- Revenue
- OMCC $9,366,000.00
- ACRV N/A
- Revenue This Year
- OMCC N/A
- ACRV N/A
- Revenue Next Year
- OMCC N/A
- ACRV N/A
- P/E Ratio
- OMCC N/A
- ACRV N/A
- Revenue Growth
- OMCC N/A
- ACRV N/A
- 52 Week Low
- OMCC $4.21
- ACRV $1.05
- 52 Week High
- OMCC $7.00
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- ACRV 55.88
- Support Level
- OMCC N/A
- ACRV $1.15
- Resistance Level
- OMCC N/A
- ACRV $1.38
- Average True Range (ATR)
- OMCC 0.00
- ACRV 0.09
- MACD
- OMCC 0.00
- ACRV 0.02
- Stochastic Oscillator
- OMCC 0.00
- ACRV 83.33
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp is a specialized consumer finance company. The Company now operates as a holding company which indirectly owns a controlling interest in a broadband company. The Company announced the restructuring of its operation.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.